Novartis, DNDi to develop new oral drug for visceral leishmaniasis
Novartis will complete the Phase 1 clinical trials, while DNDi will lead Phase 2 and Phase 3 clinical…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
26 Feb 20
Novartis will complete the Phase 1 clinical trials, while DNDi will lead Phase 2 and Phase 3 clinical…
19 Feb 20
WuXi Vaccines is a joint venture vaccine Contract Development and Manufacturing Organization (CDMO) between WuXi Biologics and Shanghai…
Pheno Therapeutics will investigate new multiple sclerosis treatments using technology and expertise from the University of Edinburgh
14 Jan 20
The collaboration includes three projects that tackle the CVD challenge and provides enhanced opportunities for life science sector…
18 Dec 19
CytoDyn intends to obtain FDA approval for leronlimab in combination therapy, and file a biologics license application (BLA)…
22 Nov 19
bNAbs are the antibodies capable of recognising and blocking the entry of different strains of HIV into healthy…
04 Oct 19
The MedicaSafe SmartKey records details of each dispensation and transfers data to a cloud portal for prescriber review
19 Sep 19
In January 2019, the National Medical Products Administration has approved the use of LINZESS for adults with IBS-C…
26 Aug 19
Gilead Sciences is a research-based biopharmaceutical company engaged in discovery, development and commercialisation of medication